Having started life selling calcium supplements from above a shop in provincial England, Shire has emerged three decades later as one of the most prized assets in the European healthcare sector

June 23, 2014 9:39 pm

Shire a jewel in crown among drugmakers

By Andrew Ward, Pharmaceuticals Correspondent

Having started life selling calcium supplements from above a shop in provincial England, Shire has emerged three decades later as one of the most prized assets in the European healthcare sector.

On Friday, months of speculation over which big pharmaceuticals group would make the first move for Shire came to an end when AbbVie confirmed it had made a £27bn takeover proposal.

Flemming Ornskov, Shire chief executive, made clear on Monday that AbbVie – or any other suitor – would have to bid much higher than the latest £46.11 per share cash and stock offer made by the Chicago-based company. Read more of this post

Advertisements

Can Data From Your Fitbit Transform Medicine? Doctors Study Wearable Gadgets to See If They Motivate, Collecting Data in Process

Can Data From Your Fitbit Transform Medicine?

Doctors Study Wearable Gadgets to See If They Motivate, Collecting Data in Process

image001-1

ELIZABETH DWOSKIN and JOSEPH WALKER

June 23, 2014 6:07 p.m. ET

A group of retirees wore these trackers to monitor physical activity. Jenn Ackerman for The Wall Street Journal

Many runners and fitness fanatics have been quick to embrace wearable wireless tracking devices for measuring physical activity and calories burned. Now, a growing number of physicians are formally studying whether such “wearables” can improve patients’ health by spurring people to get moving. Read more of this post

Apple, Google, Samsung vie to bring health apps to wearables

Apple, Google, Samsung vie to bring health apps to wearables

1:14am EDT

By Christina Farr

SAN FRANCISCO (Reuters) – For decades, medical technology firms have searched for ways to let diabetics check blood sugar easily, with scant success. Now, the world’s largest mobile technology firms are getting in on the act.

Apple Inc, Samsung Electronics Co and Google Inc, searching for applications that could turn nascent wearable technology like smartwatches and bracelets from curiosities into must-have items, have all set their sites on monitoring blood sugar, several people familiar with the plans say. Read more of this post

The Gluten-Free Craze: Is It Healthy? Experts Question Benefits of Gluten-Free For All but a Small Minority

The Gluten-Free Craze: Is It Healthy?

Experts Question Benefits of Gluten-Free For All but a Small Minority

JULIE JARGON

June 22, 2014 10:37 p.m. ET

image001-7 image002-6

Consumers are inundated with competing claims about how – and what — they should eat.  Even a once tiny trend like the gluten-free diet has turned into a blockbuster. But is a diet without gluten really healthy? Read more of this post

Apex Healthcare Bhd’s transformation into a healthcare group from a pharmaceutical-based company has put it on a stronger footing in terms of revenue and earnings

Updated: Monday June 23, 2014 MYT 9:11:05 AM

Apex on stronger footing; expands pharmaceutical, consumer products

BY JOSEPH CHIN

image001-2

Dr Kee:‘Orthopaedics surgery is growing due to the ageing population.

PETALING JAYA: Apex Healthcare Bhd’s transformation into a healthcare group from a pharmaceutical-based company has put it on a stronger footing in terms of revenue and earnings. Read more of this post

Heart to heart: Tax benefits aside, Medtronic’s deal with Covidien makes sense

Heart to heart: Tax benefits aside, Medtronic’s deal with Covidien makes sense

Jun 21st 2014 | NEW YORK | From the print edition

WHEN Medtronic, a maker of stents, pacemakers and other medical devices, said on June 15th that it would buy Covidien, a competitor, for $43 billion, it gave a variety of reassurances to anxious American politicians. To be sure, the deal will let Medtronic reap the benefits of being based in Ireland for tax purposes, as Covidien already is (see article). But Medtronic is promising that its operational headquarters will stay in America and that it will invest an extra $10 billion to develop new technology there, supporting local jobs. And, beyond the tax gains, there are good business reasons for Medtronic to want to buy Covidien. Read more of this post

With Efforts to Buy Shire, AbbVie Tries to Join Rush to Go Abroad

With Efforts to Buy Shire, AbbVie Tries to Join Rush to Go Abroad

By DAVID GELLES and CHAD BRAY

JUNE 20, 2014 5:43 AM Comment

Updated, 7:08 p.m. | At first it was a trickle. A few relatively unknown pharmaceutical companies acquired international competitors, and moved their headquarters abroad.

Then the pace picked up. Bigger health care companies, including Pfizer andMedtronic, also sought to relocate overseas, claiming that doing so would lower their tax rate and allow them to access trapped cash. Competitors felt pressure to match those financial advantages and began looking for deals of their own. Read more of this post

%d bloggers like this: